Skip to main content
Top
Published in: Current Neurology and Neuroscience Reports 11/2016

01-11-2016 | Epilepsy (CW Bazil, Section Editor)

Prevention of Epilepsy: Issues and Innovations

Authors: Dieter Schmidt, Matti Sillanpää

Published in: Current Neurology and Neuroscience Reports | Issue 11/2016

Login to get access

Abstract

Epilepsy is a common brain disease and preventing epilepsy is a very relevant public health concern and an urgent unmet need. Although 40 % of all epilepsy cases are thought to have acquired causes, there is a roadblock for successful prevention. Efforts to protect the brain from epileptogenic insults are severely hampered by our lack of biomarkers to identify the few percent at high risk meriting treatment among those exposed. Preventing brain injury has been moderately effective from around birth to middle age; however, the strategy has failed to stop a substantial increase over the last decades in symptomatic epilepsy in those aged 65 and above. The traditional concept of repurposing anti-seizure drugs used for symptomatic seizure relief to prevent the onset of epilepsy has completely failed up to now. More recently, however, hope is on the horizon with a search for biomarkers and discovery of a new class of agents, called anti-epileptogenic drugs, which were specifically developed for prevention of epilepsy.
Literature
1.
go back to reference Löscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev. 2010;62:668–700.CrossRefPubMedPubMedCentral Löscher W, Brandt C. Prevention or modification of epileptogenesis after brain insults: experimental approaches and translational research. Pharmacol Rev. 2010;62:668–700.CrossRefPubMedPubMedCentral
2.
go back to reference Dichter MA. Emerging concepts in the pathogenesis of epilepsy and epileptogenesis. Arch Neurol. 2009;66:443–7.CrossRefPubMed Dichter MA. Emerging concepts in the pathogenesis of epilepsy and epileptogenesis. Arch Neurol. 2009;66:443–7.CrossRefPubMed
3.•
go back to reference Löscher W, Hirsch LJ, Schmidt D. The enigma of the latent period in the development of symptomatic acquired epilepsy—traditional view versus new concepts. Epilepsy Behav. 2015;52(Pt A):78–92. An important article about the latent period as a window of therapeutic opportunity for preventions trial in epilepsy.CrossRefPubMed Löscher W, Hirsch LJ, Schmidt D. The enigma of the latent period in the development of symptomatic acquired epilepsy—traditional view versus new concepts. Epilepsy Behav. 2015;52(Pt A):78–92. An important article about the latent period as a window of therapeutic opportunity for preventions trial in epilepsy.CrossRefPubMed
4.
go back to reference Sloviter RS, Bumanglag AV. Defining “epileptogenesis” and identifying “antiepileptogenic targets” in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology. 2012;69:3–15.CrossRefPubMedPubMedCentral Sloviter RS, Bumanglag AV. Defining “epileptogenesis” and identifying “antiepileptogenic targets” in animal models of acquired temporal lobe epilepsy is not as simple as it might seem. Neuropharmacology. 2012;69:3–15.CrossRefPubMedPubMedCentral
5.
go back to reference Temkin NR. Preventing and treating posttraumatic seizures: the human experience. Epilepsia. 2009;50 Suppl 2:10–3.CrossRefPubMed Temkin NR. Preventing and treating posttraumatic seizures: the human experience. Epilepsia. 2009;50 Suppl 2:10–3.CrossRefPubMed
6.
go back to reference Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov. 2013;12:757–76.CrossRefPubMed Löscher W, Klitgaard H, Twyman RE, Schmidt D. New avenues for antiepileptic drug discovery and development. Nat Rev Drug Discov. 2013;12:757–76.CrossRefPubMed
8.•
go back to reference Sillanpää M, Gissler M, Schmidt D. Efforts in epilepsy prevention in the last 40 years: lessons from a large nationwide study. JAMA Neurol. 2016;73(4):390–5. An important article showing that we failed to prevent epilepsy in people below age 65 and a massive increase in epilepsy in the elderly.CrossRefPubMed Sillanpää M, Gissler M, Schmidt D. Efforts in epilepsy prevention in the last 40 years: lessons from a large nationwide study. JAMA Neurol. 2016;73(4):390–5. An important article showing that we failed to prevent epilepsy in people below age 65 and a massive increase in epilepsy in the elderly.CrossRefPubMed
10.
11.
go back to reference Sloviter RS. Progress on the issue of excitotoxic injury modification vs. real neuroprotection; implications for post-traumatic epilepsy. Neuropharmacology. 2011;61(5-6):1048–50.CrossRefPubMed Sloviter RS. Progress on the issue of excitotoxic injury modification vs. real neuroprotection; implications for post-traumatic epilepsy. Neuropharmacology. 2011;61(5-6):1048–50.CrossRefPubMed
13.
go back to reference Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epilept Disord. 2012;14:105–13. Schmidt D. Is antiepileptogenesis a realistic goal in clinical trials? Concerns and new horizons. Epilept Disord. 2012;14:105–13.
15.•
go back to reference Pitkänen A, Löscher W, Vezzani A, et al. Advances in the development of biomarkers for epilepsy. Lancet Neurol. 2016;15(8):843–56. A good overview showing where how we stand in the discovery of biomarkers for epilepsy development.CrossRefPubMed Pitkänen A, Löscher W, Vezzani A, et al. Advances in the development of biomarkers for epilepsy. Lancet Neurol. 2016;15(8):843–56. A good overview showing where how we stand in the discovery of biomarkers for epilepsy development.CrossRefPubMed
16.
go back to reference Baulac M, de Boer H, Elger C, et al. Epilepsy priorities in Europe: a report of the ILAE-IBE Epilepsy Advocacy Europe Task Force. Epilepsia. 2015;56(11):1687–95.CrossRefPubMedPubMedCentral Baulac M, de Boer H, Elger C, et al. Epilepsy priorities in Europe: a report of the ILAE-IBE Epilepsy Advocacy Europe Task Force. Epilepsia. 2015;56(11):1687–95.CrossRefPubMedPubMedCentral
17.
go back to reference Schmidt D. Chapter 5 antiepileptic drug development. In: Shorvon SD, Perucca E, Engel Jr J, editors. Treatment of epilepsy. 4th ed. Newark: Wiley-Blackwell; 2015. p. 61–74.CrossRef Schmidt D. Chapter 5 antiepileptic drug development. In: Shorvon SD, Perucca E, Engel Jr J, editors. Treatment of epilepsy. 4th ed. Newark: Wiley-Blackwell; 2015. p. 61–74.CrossRef
18.
Metadata
Title
Prevention of Epilepsy: Issues and Innovations
Authors
Dieter Schmidt
Matti Sillanpää
Publication date
01-11-2016
Publisher
Springer US
Published in
Current Neurology and Neuroscience Reports / Issue 11/2016
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-016-0695-9

Other articles of this Issue 11/2016

Current Neurology and Neuroscience Reports 11/2016 Go to the issue

Epilepsy (CW Bazil, Section Editor)

Treatment of Epilepsy in the Elderly

Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

Hypothalamic Dysfunction and Multiple Sclerosis: Implications for Fatigue and Weight Dysregulation

Headache (RB Halker, Section Editor)

Headaches: a Review of the Role of Dietary Factors